| Ident. | Authors (with country if any) | Title |
|---|
| 000273 |
Andreas Kupsch [Allemagne] ; Michele Tagliati [États-Unis] ; Marie Vidailhet [France] ; Tipu Aziz [Royaume-Uni] ; Paul Krack [France] ; Elena Moro [Canada] ; Joachim K. Krauss [Allemagne] | Early Postoperative Management of DBS in Dystonia: Programming, Response to Stimulation, Adverse Events, Medication Changes, Evaluations, and Troubleshooting |
| 000278 |
Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Ounn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; SANG JIN KIM [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis] | Differential Response of Speed, Amplitude, and Rhythm to Dopaminergic Medications in Parkinson's Disease |
| 000629 |
Valerie Voon [États-Unis, Canada] ; Susan H. Fox [Canada] | Medication-related impulse control and repetitive behaviors in parkinson disease |
| 000675 |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 000700 |
V. Voon [États-Unis, Canada] ; K. Hassan [Canada] ; M. Zurowski [Canada] ; S. Duff-Canning [Canada] ; M. De Souza [Canada] ; S. Fox [Canada] ; A. E. Lang [Canada] ; J. Miyasaki [Canada] | Prospective prevalence of pathologic gambling and medication association in Parkinson disease |
| 000734 |
Andrew R. Willan [Canada] ; Ron Goeree [Canada] ; Eleanor M. Pullenayegum [Canada] ; Christopher Mcburney [États-Unis] ; Gordon Blackhouse [Canada] | Economic evaluation of rivastigmine in patients with parkinson's disease dementia |
| 000785 |
Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
| 000822 |
Brad Hagen [Canada] ; Chris Armstrong Esther [Canada] ; Roland Ikuto [Canada] ; Robert J. Williams [Canada] ; Carole-Lynne Le Navenec [Canada] ; Morgan Aho | Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation |
| 000830 |
Colleen P. Millikin [Canada] ; Lisa L. Trepanier [Canada] ; Sean B. Rourke [Canada] | Verbal fluency component analysis in adults with HIV/AIDS |
| 000908 |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
| 000910 |
Pierre J. Blanchet [Canada] | The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects |
| 000920 |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
| 000922 |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 000927 |
Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada] | Poor tolerability of a transdermal nicotine treatment in Parkinson's disease |
| 000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 000941 |
Ajit Kumar [Canada] ; ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] | Mechanisms of motor complications in treatment of Parkinson's disease |
| 000952 |
Yoshiaki Furukawa [Canada] | Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss |
| 000965 |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
| 000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| 000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000979 |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease |
| 000984 |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000987 |
H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada] | Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study |
| 000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
| 000A29 |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
| 000A37 |
Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada] | Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa |
| 000A38 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
| 000A51 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 000A65 |
Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model |
| 000A66 |
Erik Ch. Wolters [Pays-Bas] | Psychiatric complications in the treatment of Parkinson's disease |
| 000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
| 000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000A83 |
A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada] | Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats |
| 000A87 |
M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
| 000A89 |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
| 000B03 |
John G. Nutt [États-Unis] | Fluctuations in response to treatment for Parkinson's disease |
| 000B07 |
Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease |
| 000B15 |
Moussa B. H. Youdim [Israël] ; Edna Grünblatt [Israël] ; Yona Levites-Royak [Israël] ; Silvia Mandel [Israël] | Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expression |
| 000B17 |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
| 000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B31 |
Heikki Ter V Inen [Finlande] ; Urpo Rinne [Finlande] ; Ariel Gordin [Finlande] | Catechol-O-methyltransferase inhibitors in Parkinson's disease |
| 000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000B33 |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
| 000B35 |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
| 000B36 |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| 000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000C06 |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
| 000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
| 000C12 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 000C19 |
D. A. Grimes [Canada] ; A. E. Lang | Treatment of early Parkinson's disease |
| 000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C28 |
D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada] | Ropinirole and pramipexole, the new agonists |
| 000C31 |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
| 000C37 |
K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
| 000C45 |
D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada] | Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration |
| 000C47 |
T. Mendis [Canada] ; O. Suchowersky [Canada] ; A. Lang [Canada] ; S. Gauthier [Canada] | Management of Parkinson's disease : A review of current and new therapies |
| 000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
| 000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
| 000C70 |
J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada] | COMT inhibitors in Parkinson's disease |
| 000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
| 000C75 |
M. A. Bedard [Canada] ; B. Pillon [France] ; B. Dubois [France] ; N. Duchesne [Canada] ; H. Masson [Canada] ; Yves Agid [France] | Acute and long-term administration of anticholinergics in Parkinson's disease : Specific effects on the subcortico-frontal syndrome |
| 000C77 |
T. L. Sourkes [Canada] | "Rational hope" in the early treatment of Parkinson's disease |
| 000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
| 000C81 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon : A double-blind, placebo-controlled, multicenter trial |
| 000C99 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 000D05 |
J. H. Growdon [États-Unis] ; K. Kieburtz [Canada] ; M. P. Mcdermott [Canada] ; M. Panisset [Canada] ; J. H. Friedman [États-Unis] | Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients |
| 000D25 |
M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France] | Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist |
| 000D50 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial |
| 000D51 |
L. Thorpe [Canada] | The treatment of psychotic disorders in late life |
| 000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
| 000D68 |
P. A. Rochon [Canada] ; J. H. Gurwitz [États-Unis] | Optimising drug treatment for elderly people : the prescribing cascade |
| 000D72 |
M. Mamelak [Canada] | Neurodegeneration, sleep, and cerebral energy metabolism : A testable hypothesis |
| 000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
| 000D86 |
W. D. Hutchison [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Effects of apomorphine on globus pallidus neurons in parkinsonian patients |
| 000D90 |
M. Guttman [Canada] | Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease |
| 000D93 |
P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide |
| 000E07 |
MANOHAR LAL THAKUR [Canada] ; UMA SHANKAR SRIVASTAVA [Canada] | Vitamin-E metabolism and its application |
| 000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
| 000E13 |
P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
| 000E14 |
N. Galvez-Jimenez [Canada] ; A. E. Lang [Canada] | Perioperative problems in Parkinson's disease and their management : Apomorphine with rectal domperidone |
| 000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 000E31 |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis] | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates |
| 000E34 |
C. V. Borlongan [États-Unis] ; T. B. Freeman ; R. A. Hauser ; D. W. Cahill ; P. R. Sanberg ; R. R. Tasker | Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism : Relevance to neural transplantation. Commentary |
| 000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
| 000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
| 000E54 |
D. V. Exner [Canada] ; T. Muzyka ; A. M. Gillis | Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine |
| 000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
| 000E82 |
| |
| 000E92 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 000F00 |
P. H. Yu [Canada] | Pharmacological and clinical implications of MAO-B inhibitors |
| 000F12 |
A. H. Rajput [Canada] ; W. R. G. Gibb ; X. H. Zhong ; K. S. Shannak ; S. Kish ; L. G. Chang ; O. Hornykiewicz | Dopa-responsive dystonia : pathological and biochemical observations in a case |
| 000F19 |
D. B. Calne [Canada] | Treatment of Parkinson's disease |
| 000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 000F61 |
| 3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991 |
| 000F68 |
M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
| 000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 001013 |
R. Rivest ; S. St-Pierre ; F. B. Jolicoeur | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat |
| 001030 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
| 001032 |
O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001070 |
J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
| 001074 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
| 001075 |
A. E. Lang ; D. E. Riley ; L. Vachon ; X. Lataste | CQA 206-291 in Parkinson's disease : an acute single escalating dosage study |
| 001082 |
J. K. Tsui ; S. Ross ; K. Poulin ; J. Douglas ; D. Postnikoff ; S. Calne ; W. Woodward ; D. B. Calne | The effect of dietary protein on the efficacy of L-dopa: a double-blind study |
| 001084 |
W. G. Vincken ; C. M. Darauay ; M. G. Cosio | Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease |
| 001095 |
M. Dubuc ; T. Kus ; M. A. Campa ; C. Lambert ; M. Rosengarten ; MOHAMMAD SHENASA | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome |
| 001100 |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
| 001102 |
O. Fujimura ; G. J. Klein ; A. D. Sharma ; R. Yee ; T. Szabo | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome |
| 001104 |
J. K. C. Tsui ; E. C. Wolters ; R. F. Peppard ; D. B. Calne | A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease |
| 001116 |
J. D. Grimes ; M. N. Hassan ; J. H. Thakar | Prevention of progression of Parkinson's disease with antioxidative therapy |
| 001117 |
D. Riley ; A. E. Lang | Practical application of a low-protein diet for Parkinson's disease |
| 001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 001138 |
J. A. Sharpe ; W. A. Fletcher ; A. E. Lang ; D. H. Zackon | Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease |
| 001144 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Parkinson's disease: cognitive changes in relation to treatment response |
| 001147 |
H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
| 001151 |
L. Brent Mitchell ; D. G. Wyse ; H. J. Duff | Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome |
| 001152 |
MOHAMMAD SHENASA ; M. Fromer ; G. Faugere ; R. Nadeau ; R. A. Leblanc ; C. Lambert ; MOHAMMAD ALI SADR-AMELI | Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome |
| 001159 |
I. Libman ; M. J. Gawel ; R. J. Riopelle ; S. Bouchard | A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of "De Novö Parkinson's disease patients |
| 001167 |
C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
| 001172 |
J. H. Moss ; D. E. Stewart | Iatrogenic Parkinsonism in Huntington's chorea |
| 001176 |
E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
| 001178 |
M. Guttman ; P. Seeman ; G. P. Reynolds ; P. Riederer ; K. Jellinger ; W. W. Tourtellotte | Dopamine D2 receptor density remains constant in treated Parkinson's disease |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
| 001196 |
A. H. Rajput ; W. Stern ; W. H. Laverty | Chronic low-dose levodopa therapy in Parkinsońs disease: an argument for delaying levodopa therapy |
| 001198 |
J. D. Grimes ; D. B. King ; O. S. Kofman ; P. Molina-Negro ; A. F. Wilson ; S. Bouchard | Bromocriptine in the management of end of dose deterioration in Parkinson's disease |
